Company Intelligence
Akeso
康方生物
No Known BCC Exposure
Akeso is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. Licensing ivonescimab or other Akeso assets does not create federal contracting risk.
Overview
Akeso (康方生物) is a clinical-stage biopharmaceutical company that has emerged as a global leader in bispecific antibody development. Its flagship asset ivonescimab (PD-1/VEGF bispecific) is the most advanced bispecific in the PD-1/VEGF class globally and has generated intense competitive interest from Big Pharma — it was the asset that prompted BMS's $11.1B deal with BioNTech for competing program BNT-327.
Key Facts
- Ivonescimab (PD-1/VEGF bispecific) is first-in-class and the most advanced globally in this mechanism
- Demonstrated superiority over pembrolizumab in first-line NSCLC — a potential blockbuster result
- Triggered BMS's $11.1B BioNTech deal for competing BNT-327 program
- CDE-expedited review pathway for multiple indications
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Summit Therapeutics | 2022 | $5B+ | Ivonescimab ex-China rights (oncology) |
Corporate Structure
Cayman Islands holding company, Hong Kong-listed. Founded by Dr. Xia Yu (夏瑜), formerly of Merck and PDL BioPharma. Operating entities in Zhongshan and Guangzhou.